

**Experiment Number:** 20601 - 03  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Antimony trioxide  
**CAS Number:** 1309-64-4

**Date Report Requested:** 10/15/2014  
**Time Report Requested:** 14:20:05  
**First Dose M/F:** 09/22/08 / 09/22/08  
**Lab:** BNW

F1\_Core\_RE

<b>NTP Study Number:</b>	C20601		
<b>Lock Date:</b>	06/13/2011		
<b>Cage Range:</b>	ALL		
<b>Date Range:</b>	ALL		
<b>Reasons For Removal:</b>	25021 TSAC	25020 NATD	25019 MSAC
<b>Removal Date Range:</b>	ALL		
<b>Treatment Groups:</b>	Include ALL		
<b>Study Gender:</b>	Both		
<b>TDMSE Version:</b>	3.0.2.2_002		
<b>PWG Approval Date:</b>	NONE		

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
----------------------	---------	---------	----------	----------

## Disposition Summary

Animals Initially In Study	60	60	60	60
Early Deaths				
Moribund Sacrifice	15	19	22	29
Natural Death	5	1		3
Survivors				
Terminal Sacrifice	30	30	28	18
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(49)	(50)	(50)	(49)
Necrosis				1 (2%)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Edema	1 (2%)			
Inflammation, Chronic Active	1 (2%)			
Intestine Large, Rectum	(44)	(49)	(48)	(48)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Intestine Small, Duodenum	(47)	(50)	(50)	(49)
Fibrosis			1 (2%)	
Inflammation, Chronic Active		1 (2%)		
Intestine Small, Ileum	(48)	(50)	(50)	(49)
Hemorrhage				1 (2%)
Inflammation, Suppurative				1 (2%)
Inflammation, Chronic Active			1 (2%)	
Necrosis			1 (2%)	
Epithelium, Atrophy				1 (2%)
Intestine Small, Jejunum	(46)	(49)	(50)	(48)
Fibrosis	1 (2%)			
Inflammation, Chronic Active	1 (2%)			
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	3 (6%)	4 (8%)	1 (2%)
Basophilic Focus	3 (6%)	5 (10%)	5 (10%)	1 (2%)
Clear Cell Focus	18 (36%)	14 (28%)	15 (30%)	8 (16%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/Wistar Han

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 10/15/2014

Time Report Requested: 14:20:05

First Dose M/F: 09/22/08 / 09/22/08

Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Congestion	3 (6%)	8 (16%)	6 (12%)	6 (12%)
Cyst	2 (4%)	4 (8%)	2 (4%)	1 (2%)
Eosinophilic Focus		1 (2%)	1 (2%)	2 (4%)
Fatty Change	4 (8%)	8 (16%)	4 (8%)	3 (6%)
Fibrosis		1 (2%)		1 (2%)
Hematopoietic Cell Proliferation				1 (2%)
Hepatodiaphragmatic Nodule		2 (4%)	3 (6%)	1 (2%)
Inflammation, Chronic Active	2 (4%)		1 (2%)	1 (2%)
Mineralization		1 (2%)		
Mixed Cell Focus		1 (2%)		
Necrosis		1 (2%)	1 (2%)	2 (4%)
Bile Duct, Cyst, Multiple				1 (2%)
Bile Duct, Dilatation			1 (2%)	
Bile Duct, Hyperplasia				3 (6%)
Sinusoid, Dilatation	1 (2%)			
Vein, Dilatation		1 (2%)		
Mesentery	(50)	(50)	(50)	(50)
Arteriole, Inflammation, Chronic Active	1 (2%)			
Artery, Inflammation, Chronic Active				6 (12%)
Artery, Necrosis				3 (6%)
Fat, Necrosis	1 (2%)	4 (8%)	3 (6%)	2 (4%)
Pancreas	(50)	(50)	(50)	(50)
Atrophy	15 (30%)	12 (24%)	14 (28%)	20 (40%)
Basophilic Focus	3 (6%)	4 (8%)		
Inflammation, Chronic Active	1 (2%)		2 (4%)	2 (4%)
Arteriole, Inflammation, Chronic Active			1 (2%)	1 (2%)
Artery, Hemorrhage			1 (2%)	
Artery, Inflammation, Chronic Active	1 (2%)		2 (4%)	8 (16%)
Artery, Necrosis			1 (2%)	4 (8%)
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy		2 (4%)		2 (4%)
Basophilic Focus		1 (2%)		
Inflammation, Suppurative		1 (2%)		
Stomach, Forestomach	(50)	(50)	(50)	(50)
Cyst, Squamous	1 (2%)			
Edema				2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20601 - 03  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
**CAS Number:** 1309-64-4

**Date Report Requested:** 10/15/2014  
**Time Report Requested:** 14:20:05  
**First Dose M/F:** 09/22/08 / 09/22/08  
**Lab:** BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hyperplasia, Squamous	2 (4%)	7 (14%)	4 (8%)	7 (14%)
Inflammation, Suppurative		1 (2%)		
Inflammation, Chronic Active			1 (2%)	
Ulcer	1 (2%)			1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Edema				1 (2%)
Erosion				1 (2%)
Fibrosis		1 (2%)		
Hemorrhage				1 (2%)
Inflammation, Chronic Active	1 (2%)		1 (2%)	3 (6%)
Metaplasia, Squamous			1 (2%)	
Mineralization	1 (2%)		1 (2%)	1 (2%)
Ulcer		1 (2%)		
Arteriole, Mineralization		1 (2%)		
Capillary, Hyperplasia				1 (2%)
Tongue	(1)	(1)	(0)	(1)
Epithelium, Hyperplasia	1 (100%)			1 (100%)
Tooth	(2)	(1)	(1)	(1)
Inflammation, Suppurative		1 (100%)		
Inflammation, Chronic Active			1 (100%)	1 (100%)
Malformation	2 (100%)			

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(50)	(50)	(50)	(49)
Angiomatous Hyperplasia			1 (2%)	
Mineralization	1 (2%)		1 (2%)	
Heart	(50)	(50)	(50)	(50)
Angiectasis				1 (2%)
Cardiomyopathy	41 (82%)	44 (88%)	42 (84%)	40 (80%)
Hemorrhage			1 (2%)	
Inflammation, Chronic Active				1 (2%)
Thrombosis				2 (4%)
Artery, Inflammation, Chronic Active				1 (2%)
Valve, Fibrosis			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Valve, Inflammation, Suppurative				1 (2%)
Valve, Thrombosis				2 (4%)
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule		1 (2%)	1 (2%)	
Angiectasis		2 (4%)		3 (6%)
Atrophy	1 (2%)		2 (4%)	
Degeneration, Cystic	3 (6%)		1 (2%)	3 (6%)
Hematopoietic Cell Proliferation				1 (2%)
Hemorrhage	1 (2%)			
Hyperplasia	30 (60%)	32 (64%)	33 (66%)	32 (64%)
Vacuolization Cytoplasmic	1 (2%)			
Adrenal Medulla	(49)	(50)	(49)	(50)
Degeneration, Fatty				1 (2%)
Hyperplasia	1 (2%)	2 (4%)	4 (8%)	8 (16%)
Thrombosis				1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(49)
Parathyroid Gland	(44)	(46)	(46)	(48)
Fibrosis			1 (2%)	
Hyperplasia	4 (9%)		1 (2%)	1 (2%)
Pituitary Gland	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)			
Cyst		1 (2%)		
Hemorrhage	1 (2%)			
Pars Distalis, Hyperplasia	11 (22%)	11 (22%)	14 (28%)	15 (30%)
Pars Intermedia, Angiectasis	1 (2%)			
Pars Intermedia, Hyperplasia	1 (2%)	4 (8%)		1 (2%)
Thyroid Gland	(50)	(50)	(50)	(50)
C-cell, Hyperplasia	9 (18%)	11 (22%)	13 (26%)	6 (12%)
Follicle, Cyst	1 (2%)	1 (2%)		
Follicular Cell, Hyperplasia	1 (2%)	2 (4%)		2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20601 - 03  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
**CAS Number:** 1309-64-4

**Date Report Requested:** 10/15/2014  
**Time Report Requested:** 14:20:05  
**First Dose M/F:** 09/22/08 / 09/22/08  
**Lab:** BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
<b>GENERAL BODY SYSTEM</b>				
Tissue NOS	(0)	(1)	(0)	(1)
<b>GENITAL SYSTEM</b>				
Coagulating Gland	(0)	(0)	(0)	(1)
Inflammation, Chronic Active				1 (100%)
Epididymis	(50)	(50)	(50)	(50)
Epithelium, Cytoplasmic Alteration	1 (2%)			
Preputial Gland	(50)	(50)	(50)	(50)
Ectasia	1 (2%)	1 (2%)	4 (8%)	
Fibrosis		1 (2%)		
Inflammation, Chronic Active	7 (14%)	5 (10%)	4 (8%)	4 (8%)
Prostate	(50)	(50)	(50)	(50)
Inflammation, Suppurative	1 (2%)	6 (12%)	5 (10%)	4 (8%)
Inflammation, Chronic Active	8 (16%)	3 (6%)	5 (10%)	3 (6%)
Epithelium, Hyperplasia	9 (18%)	18 (36%)	21 (42%)	13 (26%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Congestion				1 (2%)
Hyperplasia		1 (2%)		
Inflammation, Suppurative		1 (2%)		
Inflammation, Chronic Active	2 (4%)			1 (2%)
Epithelium, Hyperplasia	1 (2%)			
Testes	(50)	(50)	(50)	(50)
Cyst	1 (2%)			
Edema	30 (60%)	37 (74%)	31 (62%)	26 (52%)
Fibrosis		1 (2%)		
Hemorrhage			1 (2%)	
Inflammation, Chronic Active		1 (2%)	1 (2%)	
Arteriole, Inflammation, Chronic Active	1 (2%)			
Germinal Epithelium, Degeneration	3 (6%)	6 (12%)	6 (12%)	4 (8%)
Interstitial Cell, Hyperplasia	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Depletion Cellular		1 (2%)		
Fibrosis		1 (2%)		
Hyperplasia		3 (6%)	4 (8%)	8 (16%)
Lymph Node	(2)	(4)	(7)	(7)
Hyperplasia, Plasma Cell			1 (14%)	
Axillary, Hyperplasia, Plasma Cell		1 (25%)		
Axillary, Infiltration Cellular, Histiocyte				1 (14%)
Iliac, Ectasia			2 (29%)	
Iliac, Hyperplasia, Plasma Cell			1 (14%)	1 (14%)
Lumbar, Ectasia				1 (14%)
Lumbar, Hyperplasia, Plasma Cell		2 (50%)	2 (29%)	3 (43%)
Lumbar, Infiltration Cellular, Histiocyte				1 (14%)
Lumbar, Renal, Hyperplasia, Plasma Cell	1 (50%)			
Pancreatic, Congestion			1 (14%)	
Renal, Ectasia	1 (50%)			2 (29%)
Renal, Infiltration Cellular, Histiocyte				1 (14%)
Lymph Node, Bronchial	(41)	(40)	(48)	(47)
Ectasia			1 (2%)	
Foreign Body		35 (88%)	45 (94%)	42 (89%)
Hyperplasia, Lymphoid		21 (52%)	29 (60%)	26 (55%)
Pigmentation	1 (2%)	4 (10%)	5 (10%)	10 (21%)
Lymph Node, Mandibular	(45)	(46)	(48)	(45)
Hyperplasia, Plasma Cell		1 (2%)	2 (4%)	
Lymph Node, Mediastinal	(42)	(45)	(49)	(49)
Congestion				1 (2%)
Foreign Body		41 (91%)	41 (84%)	43 (88%)
Hyperplasia				1 (2%)
Hyperplasia, Lymphoid	1 (2%)	24 (53%)	30 (61%)	26 (53%)
Pigmentation	24 (57%)	23 (51%)	29 (59%)	26 (53%)
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Angiomatous Hyperplasia		1 (2%)		3 (6%)
Ectasia				2 (4%)
Fibrosis			1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hemorrhage				1 (2%)
Artery, Inflammation, Chronic Active				1 (2%)
Spleen	(50)	(50)	(50)	(50)
Accessory Spleen	1 (2%)			
Cyst		1 (2%)		
Depletion Cellular	1 (2%)		1 (2%)	1 (2%)
Depletion Cellular, Focal			1 (2%)	
Fibrosis			1 (2%)	
Hematopoietic Cell Proliferation	41 (82%)	45 (90%)	43 (86%)	46 (92%)
Hemorrhage		1 (2%)		
Mineralization				1 (2%)
Necrosis		1 (2%)		
Thymus	(41)	(35)	(47)	(45)
Cyst			1 (2%)	
Depletion Cellular	5 (12%)	6 (17%)	6 (13%)	9 (20%)
Hemorrhage	1 (2%)			
Epithelial Cell, Hyperplasia			1 (2%)	

**INTEGUMENTARY SYSTEM**

Mammary Gland	(6)	(9)	(7)	(8)
Galactocele		1 (11%)	1 (14%)	
Skin	(50)	(50)	(50)	(50)
Cyst, Squamous	2 (4%)			
Dysplasia	1 (2%)			
Foreign Body		1 (2%)		
Inflammation, Chronic Active	22 (44%)	30 (60%)	28 (56%)	32 (64%)
Ulcer	17 (34%)	23 (46%)	23 (46%)	28 (56%)
Epidermis, Hyperplasia		1 (2%)		
Hair Follicle, Hyperplasia				1 (2%)
Subcutaneous Tissue, Hemorrhage	1 (2%)			
Subcutaneous Tissue, Inflammation, Granulomatous	1 (2%)		1 (2%)	
Subcutaneous Tissue, Inflammation, Chronic Active			1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Inflammation, Chronic Active			1 (2%)	
Epiphysis, Femur, Cyst			1 (2%)	
Femur, Hyperostosis		1 (2%)		
Mandible, Cyst, Squamous			1 (2%)	
Maxilla, Cyst, Squamous		1 (2%)		
Maxilla, Inflammation, Chronic Active	3 (6%)	4 (8%)	2 (4%)	1 (2%)
Vertebra, Fibrosis		1 (2%)		
Skeletal Muscle	(4)	(3)	(3)	(5)
Atrophy		1 (33%)		
Cyst				1 (20%)
Hemorrhage	1 (25%)			
Inflammation, Chronic Active				1 (20%)
Necrosis			1 (33%)	
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Compression	7 (14%)	11 (22%)	8 (16%)	2 (4%)
Hemorrhage	1 (2%)			
Meninges, Hyperplasia			1 (2%)	1 (2%)
Peripheral Nerve	(3)	(3)	(2)	(0)
Degeneration		1 (33%)	1 (50%)	
Spinal Cord	(3)	(3)	(1)	(0)
<b>RESPIRATORY SYSTEM</b>				
Larynx	(50)	(50)	(50)	(50)
Foreign Body		50 (100%)	50 (100%)	50 (100%)
Hyperplasia, Squamous				2 (4%)
Inflammation, Chronic Active	2 (4%)	5 (10%)	2 (4%)	4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Metaplasia, Squamous		2 (4%)		1 (2%)
Mineralization			1 (2%)	
Necrosis	1 (2%)			1 (2%)
Respiratory Epithelium, Hyperplasia	2 (4%)	4 (8%)	1 (2%)	
Lung	(50)	(50)	(50)	(50)
Congestion		1 (2%)		
Fibrosis	2 (4%)	50 (100%)	49 (98%)	49 (98%)
Foreign Body	1 (2%)	50 (100%)	50 (100%)	50 (100%)
Hemorrhage	2 (4%)	2 (4%)	1 (2%)	3 (6%)
Inflammation, Chronic Active	18 (36%)	50 (100%)	50 (100%)	50 (100%)
Metaplasia, Osseous	1 (2%)	2 (4%)	2 (4%)	9 (18%)
Proteinosis		47 (94%)	50 (100%)	50 (100%)
Alveolar Epithelium, Hyperplasia	4 (8%)	50 (100%)	48 (96%)	49 (98%)
Alveolar Epithelium, Metaplasia, Squamous			1 (2%)	
Alveolus, Inflammation, Suppurative		12 (24%)	24 (48%)	28 (56%)
Artery, Inflammation, Chronic Active			1 (2%)	1 (2%)
Bronchiole, Epithelium, Hyperplasia	3 (6%)	34 (68%)	36 (72%)	33 (66%)
Bronchus, Hyperplasia				1 (2%)
Bronchus, Inflammation, Chronic Active		1 (2%)		
Bronchus, Metaplasia, Squamous		1 (2%)		
Perivascular, Infiltration Cellular, Lymphocyte	3 (6%)	25 (50%)	19 (38%)	9 (18%)
Perivascular, Infiltration Cellular, Lymphoid				1 (2%)
Mediastinum	(0)	(1)	(2)	(10)
Artery, Inflammation, Chronic Active		1 (100%)	2 (100%)	10 (100%)
Artery, Necrosis			2 (100%)	9 (90%)
Nose	(50)	(49)	(50)	(50)
Foreign Body			17 (34%)	40 (80%)
Hyperplasia, Squamous	1 (2%)			
Inflammation, Suppurative	4 (8%)	4 (8%)	6 (12%)	7 (14%)
Inflammation, Acute				1 (2%)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Mineralization	1 (2%)			
Glands, Cyst		1 (2%)		
Glands, Respiratory Epithelium, Cyst	1 (2%)			2 (4%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	16 (32%)	15 (31%)	15 (30%)	18 (36%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Olfactory Epithelium, Atrophy			1 (2%)	
Olfactory Epithelium, Hyperplasia			1 (2%)	
Olfactory Epithelium, Metaplasia, Respiratory		1 (2%)		1 (2%)
Respiratory Epithelium, Hyperplasia	6 (12%)	15 (31%)	13 (26%)	25 (50%)
Respiratory Epithelium, Metaplasia, Squamous			2 (4%)	6 (12%)
Respiratory Epithelium, Necrosis	1 (2%)		3 (6%)	1 (2%)
Respiratory Epithelium, Regeneration				2 (4%)
Turbinate, Hyperostosis			1 (2%)	1 (2%)
Trachea	(50)	(50)	(50)	(50)
Foreign Body		28 (56%)	43 (86%)	48 (96%)
Inflammation, Suppurative		3 (6%)	1 (2%)	
Inflammation, Chronic Active				1 (2%)
Metaplasia, Squamous	1 (2%)	1 (2%)	4 (8%)	3 (6%)
Mineralization			1 (2%)	1 (2%)
Necrosis				1 (2%)
Epithelium, Hyperplasia		1 (2%)		
Epithelium, Regeneration				1 (2%)

**SPECIAL SENSES SYSTEM**

Ear	(0)	(0)	(1)	(0)
Eye	(49)	(49)	(50)	(49)
Ciliary Body, Inflammation, Acute			1 (2%)	6 (12%)
Cornea, Inflammation, Chronic Active				2 (4%)
Iris, Infiltration Cellular, Histiocyte			1 (2%)	
Lens, Degeneration	2 (4%)	5 (10%)	3 (6%)	4 (8%)
Retina, Atrophy	8 (16%)	11 (22%)	9 (18%)	6 (12%)
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia	2 (4%)	1 (2%)		3 (6%)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Lacrimal Gland	(1)	(0)	(1)	(0)
Atrophy			1 (100%)	
Hypertrophy	1 (100%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet			1 (2%)	
Amyloid Deposition		1 (2%)		
Cyst	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Fibrosis				1 (2%)
Infarct		1 (2%)	2 (4%)	1 (2%)
Inflammation, Suppurative	1 (2%)			1 (2%)
Inflammation, Chronic Active	1 (2%)			2 (4%)
Metaplasia, Osseous				1 (2%)
Nephropathy	41 (82%)	41 (82%)	40 (80%)	38 (76%)
Thrombosis		1 (2%)		
Artery, Inflammation, Chronic Active			1 (2%)	4 (8%)
Artery, Necrosis			1 (2%)	4 (8%)
Papilla, Necrosis				2 (4%)
Pelvis, Dilatation	2 (4%)	2 (4%)	1 (2%)	3 (6%)
Pelvis, Inflammation, Suppurative	2 (4%)	3 (6%)	5 (10%)	2 (4%)
Pelvis, Inflammation, Chronic Active	4 (8%)		1 (2%)	1 (2%)
Pelvis, Mineralization	16 (32%)	10 (20%)	11 (22%)	3 (6%)
Renal Tubule, Accumulation, Hyaline Droplet		1 (2%)	3 (6%)	14 (28%)
Renal Tubule, Hyperplasia	1 (2%)			1 (2%)
Renal Tubule, Mineralization	1 (2%)			2 (4%)
Vein, Thrombosis		1 (2%)		
Ureter	(0)	(1)	(0)	(0)
Urinary Bladder	(50)	(50)	(50)	(50)
Calculus Gross Observation				1 (2%)
Hemorrhage				1 (2%)
Inflammation, Suppurative	1 (2%)			
Necrosis	1 (2%)			
Serosa, Inflammation, Chronic Active				1 (2%)
Transitional Epithelium, Hyperplasia				1 (2%)

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
<b>Disposition Summary</b>				
Animals Initially In Study	60	60	60	60
Early Deaths				
Moribund Sacrifice	11	12	20	27
Natural Death			2	3
Survivors				
Moribund Sacrifice			1	
Natural Death				1
Terminal Sacrifice	39	38	27	19
Animals Examined Microscopically	50	50	50	50

#### ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(50)	(50)	(49)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Hemorrhage				1 (2%)
Necrosis				1 (2%)
Intestine Large, Rectum	(48)	(47)	(50)	(49)
Edema		1 (2%)		
Inflammation, Chronic Active		1 (2%)		
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Inflammation, Chronic Active				1 (2%)
Intestine Small, Ileum	(50)	(50)	(49)	(50)
Inflammation, Suppurative			1 (2%)	
Intestine Small, Jejunum	(50)	(50)	(49)	(49)
Liver	(50)	(50)	(50)	(50)
Angiectasis	3 (6%)	2 (4%)	1 (2%)	2 (4%)
Basophilic Focus	12 (24%)	7 (14%)	11 (22%)	6 (12%)
Clear Cell Focus	4 (8%)	5 (10%)	1 (2%)	2 (4%)
Congestion	2 (4%)	4 (8%)	1 (2%)	1 (2%)
Cyst	2 (4%)	4 (8%)	3 (6%)	1 (2%)
Degeneration			1 (2%)	
Eosinophilic Focus	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Fatty Change	6 (12%)	1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Fibrosis			4 (8%)	2 (4%)
Hepatodiaphragmatic Nodule	2 (4%)	2 (4%)	4 (8%)	4 (8%)
Hyperplasia		1 (2%)		
Infiltration Cellular, Histiocyte		1 (2%)		
Infiltration Cellular, Lymphocyte			1 (2%)	
Inflammation, Chronic Active			3 (6%)	4 (8%)
Mixed Cell Focus		1 (2%)	1 (2%)	2 (4%)
Necrosis				2 (4%)
Pigmentation, Hemosiderin		1 (2%)		
Bile Duct, Hyperplasia	3 (6%)	2 (4%)		1 (2%)
Bile Duct, Hypertrophy			1 (2%)	
Bile Duct, Inflammation, Chronic Active	1 (2%)			
Hepatocyte, Hypertrophy, Focal			1 (2%)	
Serosa, Fibrosis		1 (2%)		
Mesentery	(50)	(50)	(50)	(50)
Necrosis				1 (2%)
Artery, Inflammation, Chronic Active				6 (12%)
Artery, Necrosis				3 (6%)
Fat, Necrosis	5 (10%)	3 (6%)	3 (6%)	6 (12%)
Pancreas	(50)	(50)	(50)	(50)
Atrophy	11 (22%)	14 (28%)	9 (18%)	16 (32%)
Basophilic Focus	2 (4%)			1 (2%)
Inflammation, Chronic Active		2 (4%)	1 (2%)	
Artery, Hemorrhage				2 (4%)
Artery, Inflammation, Chronic Active			3 (6%)	8 (16%)
Artery, Necrosis				4 (8%)
Artery, Thrombosis				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy		1 (2%)		2 (4%)
Duct, Hyperplasia				1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Cyst, Squamous	1 (2%)			
Fibrosis		1 (2%)		
Hyperplasia, Squamous	4 (8%)	5 (10%)	4 (8%)	6 (12%)
Inflammation, Acute		1 (2%)		
Inflammation, Chronic Active				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20601 - 03  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
**CAS Number:** 1309-64-4

**Date Report Requested:** 10/15/2014  
**Time Report Requested:** 14:20:05  
**First Dose M/F:** 09/22/08 / 09/22/08  
**Lab:** BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Mineralization			1 (2%)	1 (2%)
Ulcer	2 (4%)	1 (2%)		
Stomach, Glandular	(50)	(50)	(50)	(50)
Hemorrhage			1 (2%)	1 (2%)
Inflammation, Chronic Active				1 (2%)
Mineralization				1 (2%)
Ulcer			1 (2%)	
Tooth	(1)	(1)	(0)	(1)
Inflammation, Chronic Active	1 (100%)			
Malformation		1 (100%)		1 (100%)

#### CARDIOVASCULAR SYSTEM

Blood Vessel	(49)	(50)	(50)	(49)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	29 (58%)	19 (38%)	29 (58%)	29 (58%)
Inflammation, Suppurative			1 (2%)	
Valve, Fibrosis				1 (2%)
Valve, Inflammation, Chronic Active			1 (2%)	

#### ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	1 (2%)			
Angiectasis				1 (2%)
Degeneration				1 (2%)
Degeneration, Cystic	37 (74%)	44 (88%)	39 (78%)	31 (62%)
Degeneration, Fatty				1 (2%)
Fibrosis		1 (2%)	1 (2%)	
Hematopoietic Cell Proliferation	1 (2%)		1 (2%)	
Hyperplasia	27 (54%)	23 (46%)	30 (60%)	23 (46%)
Hypertrophy	2 (4%)	2 (4%)		1 (2%)
Vacuolization Cytoplasmic	1 (2%)			
Adrenal Medulla	(49)	(49)	(49)	(50)
Atrophy		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hyperplasia			3 (6%)	5 (10%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)		1 (2%)	
Parathyroid Gland	(39)	(41)	(43)	(46)
Pituitary Gland	(50)	(50)	(50)	(50)
Angiectasis				2 (4%)
Necrosis			1 (2%)	
Vacuolization Cytoplasmic		1 (2%)		
Pars Distalis, Hyperplasia	22 (44%)	16 (32%)	17 (34%)	21 (42%)
Pars Intermedia, Hyperplasia	1 (2%)	2 (4%)	2 (4%)	2 (4%)
Thyroid Gland	(50)	(50)	(50)	(50)
C-cell, Hyperplasia	21 (42%)	16 (32%)	15 (30%)	8 (16%)
Follicle, Cyst				1 (2%)
Follicular Cell, Hyperplasia	3 (6%)	3 (6%)	1 (2%)	

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Clitoral Gland	(50)	(49)	(47)	(49)
Cyst			4 (9%)	
Fibrosis				1 (2%)
Inflammation, Chronic Active	2 (4%)	1 (2%)	2 (4%)	5 (10%)
Ovary	(50)	(49)	(50)	(50)
Congestion			2 (4%)	5 (10%)
Cyst	11 (22%)	10 (20%)	14 (28%)	15 (30%)
Fibrosis			2 (4%)	3 (6%)
Hemorrhage		1 (2%)		3 (6%)
Inflammation, Chronic Active				1 (2%)
Mineralization				1 (2%)
Necrosis				1 (2%)
Thrombosis			1 (2%)	1 (2%)
Granulosa Cell, Hyperplasia	1 (2%)	1 (2%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Interstitial Cell, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	
Uterus	(50)	(50)	(50)	(50)
Cyst	1 (2%)			
Dilatation	2 (4%)	3 (6%)	1 (2%)	2 (4%)
Hemorrhage				1 (2%)
Inflammation, Suppurative	1 (2%)		1 (2%)	2 (4%)
Inflammation, Chronic Active	1 (2%)	1 (2%)		
Necrosis	1 (2%)			
Thrombosis			1 (2%)	
Endometrial Glands, Hyperplasia	2 (4%)		3 (6%)	
Endometrial Glands, Metaplasia, Squamous		4 (8%)	2 (4%)	1 (2%)
Endometrium, Cyst				1 (2%)
Endometrium, Hyperplasia		1 (2%)	2 (4%)	
Endometrium, Hyperplasia, Cystic	9 (18%)	17 (34%)	6 (12%)	16 (32%)
Endometrium, Metaplasia, Squamous	1 (2%)			
Vagina	(0)	(0)	(1)	(0)

**HEMATOPOIETIC SYSTEM**

Bone Marrow	(50)	(50)	(50)	(50)
Hemorrhage			1 (2%)	
Hyperplasia	8 (16%)	5 (10%)	11 (22%)	20 (40%)
Myelofibrosis				1 (2%)
Lymph Node	(2)	(3)	(3)	(3)
Pigmentation	1 (50%)	1 (33%)		
Axillary, Ectasia			1 (33%)	
Iliac, Congestion				1 (33%)
Iliac, Hyperplasia, Plasma Cell			1 (33%)	
Lumbar, Ectasia			1 (33%)	
Lumbar, Foreign Body	1 (50%)			
Lumbar, Hyperplasia		1 (33%)		
Renal, Congestion			1 (33%)	
Renal, Hemorrhage			1 (33%)	
Thoracic, Foreign Body				1 (33%)
Lymph Node, Bronchial	(35)	(36)	(28)	(41)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Foreign Body		35 (97%)	23 (82%)	36 (88%)
Hyperplasia, Lymphoid		21 (58%)	9 (32%)	11 (27%)
Pigmentation	14 (40%)	12 (33%)	8 (29%)	18 (44%)
Lymph Node, Mandibular	(42)	(46)	(44)	(48)
Ectasia			1 (2%)	
Foreign Body		1 (2%)		5 (10%)
Lymph Node, Mediastinal	(46)	(46)	(46)	(46)
Congestion				1 (2%)
Fibrosis		1 (2%)		
Foreign Body		27 (59%)	32 (70%)	33 (72%)
Hyperplasia, Lymphoid		14 (30%)	10 (22%)	15 (33%)
Pigmentation	39 (85%)	42 (91%)	41 (89%)	41 (89%)
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Spleen	(50)	(50)	(50)	(50)
Congestion		1 (2%)	1 (2%)	
Depletion Cellular	1 (2%)			
Fibrosis		1 (2%)	1 (2%)	
Hematopoietic Cell Proliferation	44 (88%)	43 (86%)	46 (92%)	48 (96%)
Hemorrhage			1 (2%)	1 (2%)
Pigmentation			1 (2%)	1 (2%)
Artery, Inflammation, Chronic Active			1 (2%)	
Artery, Necrosis			1 (2%)	1 (2%)
Lymphoid Follicle, Atrophy	1 (2%)			
Thymus	(46)	(41)	(37)	(48)
Cyst		1 (2%)	1 (3%)	1 (2%)
Depletion Cellular	3 (7%)	1 (2%)	2 (5%)	3 (6%)
Hemorrhage		4 (10%)	2 (5%)	
Hyperplasia		1 (2%)		
Inflammation, Chronic Active				1 (2%)
Vacuolization Cytoplasmic	1 (2%)			
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Cyst				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Fibrosis			1 (2%)	1 (2%)
Galactocele	7 (14%)	9 (18%)	13 (26%)	10 (20%)
Granuloma, Lipomatous				2 (4%)
Hyperplasia	6 (12%)	3 (6%)	8 (16%)	3 (6%)
Infiltration Cellular, Histiocyte	1 (2%)			
Skin	(50)	(49)	(50)	(50)
Angiectasis	1 (2%)			1 (2%)
Cyst, Squamous		4 (8%)		1 (2%)
Fibrosis	1 (2%)			
Hyperplasia	1 (2%)			
Inflammation, Suppurative				1 (2%)
Inflammation, Chronic Active	8 (16%)	5 (10%)	9 (18%)	9 (18%)
Ulcer	2 (4%)	5 (10%)	4 (8%)	8 (16%)
Epidermis, Hyperplasia				1 (2%)
Epidermis, Necrosis			2 (4%)	
Subcutaneous Tissue, Inflammation, Chronic Active		1 (2%)		

**MUSCULOSKELETAL SYSTEM**

Bone	(50)	(50)	(50)	(50)
Femur, Degeneration				1 (2%)
Femur, Hyperostosis				2 (4%)
Femur, Osteomalacia				1 (2%)
Maxilla, Inflammation, Chronic Active		1 (2%)	2 (4%)	
Skeletal Muscle	(2)	(1)	(2)	(7)
Atrophy				1 (14%)
Inflammation, Suppurative				1 (14%)
Inflammation, Chronic Active				1 (14%)
Necrosis				1 (14%)

**NERVOUS SYSTEM**

Brain	(50)	(50)	(50)	(50)
Compression	10 (20%)	12 (24%)	12 (24%)	5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Edema			1 (2%)	
Hemorrhage			2 (4%)	2 (4%)
Infiltration Cellular, Mixed Cell		1 (2%)		
Meninges, Hyperplasia			1 (2%)	
Peripheral Nerve	(2)	(1)	(2)	(2)
Spinal Cord	(2)	(1)	(2)	(2)

RESPIRATORY SYSTEM

Larynx	(50)	(50)	(50)	(50)
Foreign Body		50 (100%)	50 (100%)	50 (100%)
Inflammation, Chronic Active		8 (16%)		3 (6%)
Metaplasia, Squamous				1 (2%)
Arteriole, Necrosis				1 (2%)
Respiratory Epithelium, Hyperplasia	5 (10%)	6 (12%)	2 (4%)	3 (6%)
Lung	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)	50 (100%)	50 (100%)	49 (98%)
Foreign Body		50 (100%)	50 (100%)	50 (100%)
Hemorrhage		5 (10%)	3 (6%)	
Hyperplasia, Lymphoid		1 (2%)		
Inflammation, Suppurative	1 (2%)			
Inflammation, Chronic Active	21 (42%)	50 (100%)	50 (100%)	50 (100%)
Mineralization	1 (2%)			
Proteinosis		50 (100%)	50 (100%)	50 (100%)
Thrombosis				1 (2%)
Alveolar Epithelium, Hyperplasia	5 (10%)	50 (100%)	49 (98%)	50 (100%)
Alveolar Epithelium, Metaplasia, Squamous		5 (10%)	3 (6%)	1 (2%)
Alveolus, Inflammation, Suppurative		5 (10%)	6 (12%)	5 (10%)
Artery, Inflammation, Chronic Active			1 (2%)	2 (4%)
Artery, Necrosis				2 (4%)
Bronchiole, Epithelium, Hyperplasia	6 (12%)	26 (52%)	25 (50%)	27 (54%)
Perivascular, Infiltration Cellular, Lymphocyte		18 (36%)	11 (22%)	8 (16%)
Mediastinum	(0)	(0)	(2)	(9)
Artery, Inflammation, Chronic Active			2 (100%)	9 (100%)
Artery, Necrosis			1 (50%)	6 (67%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Nose	(50)	(50)	(50)	(50)
Foreign Body		5 (10%)	26 (52%)	45 (90%)
Hyperplasia, Squamous			1 (2%)	
Inflammation, Suppurative	2 (4%)	6 (12%)	5 (10%)	4 (8%)
Necrosis				2 (4%)
Glands, Respiratory Epithelium, Hyperplasia			1 (2%)	
Olfactory Epithelium, Accumulation, Hyaline Droplet	9 (18%)	14 (28%)	13 (26%)	13 (26%)
Olfactory Epithelium, Atrophy				2 (4%)
Olfactory Epithelium, Degeneration				1 (2%)
Olfactory Epithelium, Metaplasia, Respiratory		1 (2%)		
Olfactory Epithelium, Necrosis				1 (2%)
Olfactory Epithelium, Vacuolization Cytoplasmic			1 (2%)	
Respiratory Epithelium, Accumulation, Hyaline Droplet		2 (4%)	2 (4%)	1 (2%)
Respiratory Epithelium, Degeneration		1 (2%)		
Respiratory Epithelium, Hyperplasia	4 (8%)	6 (12%)	7 (14%)	16 (32%)
Respiratory Epithelium, Metaplasia, Squamous		2 (4%)	3 (6%)	5 (10%)
Respiratory Epithelium, Necrosis	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Respiratory Epithelium, Regeneration			1 (2%)	
Squamous Epithelium, Hyperplasia				1 (2%)
Squamous Epithelium, Necrosis			1 (2%)	1 (2%)
Trachea	(50)	(50)	(50)	(50)
Fibrosis			1 (2%)	1 (2%)
Foreign Body		39 (78%)	47 (94%)	49 (98%)
Inflammation, Suppurative				1 (2%)
Metaplasia, Squamous	1 (2%)			
Epithelium, Hyperplasia				2 (4%)
Epithelium, Metaplasia, Squamous			1 (2%)	
Epithelium, Regeneration	1 (2%)		2 (4%)	1 (2%)

**SPECIAL SENSES SYSTEM**

Eye	(49)	(50)	(49)	(49)
Ciliary Body, Inflammation, Acute			1 (2%)	6 (12%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 03  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/Wistar Han

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 10/15/2014  
 Time Report Requested: 14:20:05  
 First Dose M/F: 09/22/08 / 09/22/08  
 Lab: BNW

Wistar Han RATS FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Lens, Degeneration		2 (4%)	2 (4%)	
Posterior Chamber, Exudate			1 (2%)	
Retina, Atrophy	6 (12%)	21 (42%)	18 (37%)	19 (39%)
Retina, Infiltration Cellular, Polymorphonuclear			1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)			
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Cyst	1 (2%)	2 (4%)		
Infarct		3 (6%)	2 (4%)	1 (2%)
Nephropathy	16 (32%)	15 (30%)	20 (40%)	24 (48%)
Arteriole, Inflammation, Chronic Active				1 (2%)
Artery, Fibrosis				1 (2%)
Artery, Inflammation, Chronic Active				2 (4%)
Artery, Necrosis			1 (2%)	2 (4%)
Papilla, Necrosis	1 (2%)			
Pelvis, Dilatation	1 (2%)			1 (2%)
Pelvis, Inflammation, Suppurative				2 (4%)
Pelvis, Inflammation, Chronic Active	2 (4%)	3 (6%)		1 (2%)
Pelvis, Mineralization	31 (62%)	30 (60%)	24 (48%)	15 (30%)
Renal Tubule, Accumulation, Hyaline Droplet			5 (10%)	11 (22%)
Renal Tubule, Hyperplasia	1 (2%)			1 (2%)
Renal Tubule, Infiltration Cellular, Polymorphonuclear			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(50)
Angiectasis				1 (2%)

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion